News

In January 2014, the company filed its NDA with the FDA for the treatment of malignant hyperthermia, a condition that can be triggered when genetically susceptible individuals come

TPI 287 is a new taxoid derivative, called as an abeotaxane, which binds to and stabilizes the assembly of microtubules similarly to commonly used taxanes, including paclitaxel (Taxol

In October 2013, the company has received approval from the European authorities for Lucentis PFS, which is a new way of administering Lucentis that is specifically designed for

In March 2009, AVEO and Biogen Idec have entered into an exclusive option and license agreement regarding the development and commercialization of AVEO’s discovery-stage ErbB3-targeted antibodies for the

The oral Impavido has been approved for the three main types of leishmaniasis, including visceral leishmaniasis, cutaneous leishmaniasis and mucosal leishmaniasis. The drug is intended for patients 12

Concordia CEO Mark Thompson noted that the acquisition of Donnatal represents an important advancement in the execution of the company’s legacy product strategy, providing substantial and sustainable revenue

A manufacturing agreement that covers all aspects of the production of the encapsulated live cells has been signed by Nuvilex and Austrianova. An initial payment has been made

MCT-485 is a very small noncoding double stranded RNA (dsRNA) molecule which has demonstrated a unique cytotoxic, oncolytic, and immune stimulating activity in in vitro models of hepatocellular

The results are being presented today in an oral session at the 9th European Breast Cancer Conference (EBCC) in Glasgow, Scotland at 9:45 AM local time. The ENCHANT-1